- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab 2018;20:5–21.
- Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes 2019;12:1973–85.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3–14.
Background
What do we already know about this topic?
- Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are among the main incretin hormones.1
- Combined GLP-1 and GIP receptor activation has been examined as a promising concept, given that the two incretins can act on pancreatic beta cells both synergistically and complementarily through distinct metabolic effects.2
- Tirzepatide is a novel dual GIP and GLP-1 agonist recently developed for type 2 diabetes (T2D).3
- Individual trials have assessed the clinical profile of tirzepatide versus different comparators.
How was this study conducted?
- This systematic review and meta-analysis assessed the efficacy and safety of tirzepatide for T2D.
- Included seven randomised, controlled trials ≥12 weeks that compared once-weekly tirzepatide with placebo or other glucose-lowering drugs.
- 6,609 adults with T2D irrespective of background glucose-lowering treatment.
- Primary outcome: HbA1c change from baseline.